ProThera, Prometic deal

ProThera granted ProMetic exclusive, worldwide rights to develop and commercialize human plasma-derived inter-alpha inhibitor proteins (IAIP). ProMetic will develop the proteins for two undisclosed pediatric Orphan indications; ProThera will assume development for all other indications. The companies will pay royalties to each other on their respective indications. ProMetic purchased an 11.3% stake in ProThera, which will be increased to 22.5% if an early stage development milestone is met. ...